NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
EpicentRx, Inc.
Canadian Cancer Trials Group
Cantonal Hospital of St. Gallen
pharmaand GmbH
University of Arizona
National Cancer Institute (NCI)
SWOG Cancer Research Network